A clear link between nonadherence and
an increased risk of hospitalization is found in our review; we also found support for the link between poor medication adherence and suicide risk. This review is associated with at least three limitations. A first limitation of this review relates to the fact that there was heterogeneity in the definition of adherence and methods to measure medication adherence. Some studies Inhibitors,research,lifescience,medical used objective measures such as MEMS and medication gaps while others used subjective methods such as patient self-report questionnaires and patient interviews. Thus, it was difficult to compare results and make selleckchem systematic conclusions. Second, study designs varied considerably, including prospective studies, retrospective data analyses and cross-sectional surveys. With different study designs, comparison of results becomes difficult. Inhibitors,research,lifescience,medical Third, due to the large amount of data identified, one criterion for inclusion in this review was study quality as measured by study size and design, which can be subjective, and recent publications were prioritized.
Despite these limitations, this is the first study, to our knowledge, to systematically and comprehensively explore both the factors and consequences of nonadherence in schizophrenia, with a particular focus on the link between nonadherence Inhibitors,research,lifescience,medical and hospitalization rates. Our review found a large amount of heterogeneity in the definition and methods used to assess medication adherence. Thus, there is a great need for future research to use a consistent definition and measure of adherence in patients with Inhibitors,research,lifescience,medical schizophrenia in order to enable an unbiased and meaningful Inhibitors,research,lifescience,medical comparison of results. Moreover, additional large, prospective adherence studies would allow us to assess the causes of nonadherence with greater accuracy
as the same patients are observed over time. Our systematic review Ganetespib IC50 identified a wide range of factors and consequences of poor adherence in schizophrenia. Based on the evidence found, the most frequently reported driver and consequence of nonadherence appeared AV-951 to be the lack of illness insight and greater risk of hospitalization, respectively. Factors positively related to adherence included a good therapeutic relationship with physician and perceiving the benefits of medication. Practicing physicians should be aware of the importance of building a therapeutic relationship with the patient based on trust as well as educating the patient on the medication’s impact on the symptoms and illness. Considering the substantial burden of nonadherence in schizophrenia on patients and society as a whole, improved adherence in schizophrenia is of great value to patients and society.